Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neuromotor Dysfunction in Early Psychosis

Neuromotor Dysfunction in Early Psychosis Neuromotor dysfunction, particularly extrapyramidal signs and symptoms (EPSS), plays an important role in the assessment and treatment of patients in the early stages of psychotic disorders such as schizophrenia. By blocking dopamine D2 receptors, antipsychotic medications can produce EPSS, including tardive dyskinesia. EPSS is also observed in a third or more of patients first presenting with a psychotic disorder, prior to initiation of antipsychotic pharmacotherapy. This suggests that abnormalities in neuromotor control may be an integral component of the brain mechanisms associated with psychosis. Atypical antipsychotic agents can alleviate psychosis without inducing EPSS. Preexisting EPSS may be corrected. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Neuromotor Dysfunction in Early Psychosis

Whitehorn, David; Kopala, Lili
Annals of Clinical Psychiatry , Volume 14 (2) – Oct 10, 2004
Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/neuromotor-dysfunction-in-early-psychosis-LDqzDhQREp
Publisher
Springer Journals
Copyright
Copyright © 2002 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1016859005849
Publisher site
See Article on Publisher Site

Abstract

Neuromotor dysfunction, particularly extrapyramidal signs and symptoms (EPSS), plays an important role in the assessment and treatment of patients in the early stages of psychotic disorders such as schizophrenia. By blocking dopamine D2 receptors, antipsychotic medications can produce EPSS, including tardive dyskinesia. EPSS is also observed in a third or more of patients first presenting with a psychotic disorder, prior to initiation of antipsychotic pharmacotherapy. This suggests that abnormalities in neuromotor control may be an integral component of the brain mechanisms associated with psychosis. Atypical antipsychotic agents can alleviate psychosis without inducing EPSS. Preexisting EPSS may be corrected.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 10, 2004

References

  • Dementia Praecox and Paraphrenia
    Kraepelin, E
  • The dose-response relationship formemory impairment by anticholinergic drugs
    McEvoy, JP; Freter, S
  • Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy
    Stip, E
  • Tardive dyskinesia
    Jeste, DV; Caligiuri, MP
  • Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone
    de Haan, L; Lavalaye, J; Linszen, D; Dingemans, PM; Booij, J
  • Is neuroleptic dysphoria a healthy response?
    Weiden, PJ; Mann, JJ; Dixon, L; Haas, G; DeChillo, N; Frances, AJ
  • Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome
    Awad, AG; Voruganti, LN; Heslegrave, RJ; Hogan, TP
  • Parkinson's disease
    Barbosa, ER; Limongi, JC; Cummings, JL
  • Huntington's disease
    Haddad, MS; Cummings, JL
  • Models of basal ganglia function and pathophysiology of movement disorders
    Wichmann, T; DeLong, MR
  • How to examine patients using the Abnormal Involuntary Movement Scale
    Munetz, MR; Benjamin, S
  • A rating scale for drug-induced akathisia
    Barnes, TR
  • A rating scale for extrapyramidal side effects
    Simpson, GM; Angus, JW
  • Extrapyramidal symptom rating scale
    Chouindard, G; Ross-Chouinard, A; Annable, L; Jones, BD
  • The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia
    Buchanan, RW; Heinrichs, DW.
  • Inter-rater reliability of the neurological examination in schizophrenia
    Sanders, RD; Forman, SD; Pierri, JN; Baker, RW; Kelley, ME; Van Kammen, DP; Keshavan, MS
  • Dosierung der Neuroleptika
    Haase, HJ
  • The handwriting test as an aid to neuroleptic dosage
    Kuenstler, U; Muller-Oerlinghausen, B
  • Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs
    Kuenstler, U; Juhnhold, U; Knapp, WH; Gertz, HJ
  • Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics
    Stip, E
  • Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
    Voruganti, L; Cortese, L; Oyewumi, L; Cernovsky, Z; Zirul, S; Awad, A
  • Serotonin-dopamine interaction and its relevance to schizophrenia
    Kapur, S; Remington, G
  • Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia
    Kapur, S; Zipursky, R; Jones, C; Remington, G; Houle, S
  • Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study
    McEvoy, JP; Stiller, RL; Farr, R
  • Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose
    McEvoy, JP; Hogarty, GE; Steingard, S
  • Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
    Kapur, S; Zipursky, RB; Remington, G
  • A positron emission tomography study of quetiapine in schizophrenia:Apreliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
    Kapur, S; Zipursky, R; Jones, C; Shammi, CS; Remington, G; Seeman, P
  • Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis
    Kapur, S; Seeman, P
  • Atypical antipsychotics: Mechanism of action
    Seeman, P
  • 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
    Kapur, S; Zipursky, RB; Remington, G; Jones, C; DaSilva, J; Wilson, AA; Houle, S
  • Risperidone in the treatment of schizophrenia
    Marder, SR; Meibach, RC
  • Extrapyramidal symptoms in patients treated with risperidone
    Simpson, GM; Lindenmayer, JP
  • Clinical experience in developing treatment regimens with the novel antipsychotic risperidone
    Kopala, LC
  • Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia
    Casey, DE
  • Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality
    Glazer, WM
  • Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
    Barnes, TR; McPhillips, MA
  • Assessment of EPSS and tardive dyskinesia in clinical trials
  • Neurotransmitter interactions in schizophrenia-therapeutic implications
    Carlsson, A; Waters, N; Carlsson, ML
  • Spontaneous and drug-induced movement disorders in schizophrenia
    Kopala, LC
  • Parkinsonism in neurolepticnaïve schizophrenic patients
    Caligiuri, MP; Lohr, JB; Jeste, DV
  • Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
    Chatterjee, A; Chakos, M; Koreen, A; Geisler, S; Sheitman, B; Woerner, M; Kane, JM; Alvir, J; Lieberman, JA
  • Risk factors for spontaneous dyskinesia in schizophrenia
    Fenton, WS; Wyatt, RJ; McGlashan, TH
  • Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
    Kopala, LC; Good, KP; Honer, WG
  • Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs
    Kopala, L; Good, K; Fredrikson, D; Whitehorn, D; Lazier, L; Honer, W
  • Basal ganglia volumes and treatment-response in never-medicated, first-episode schizophrenia patients
    Lang, DJ; Kopala, LC; Vandorpe, RA; Smith, GN; Riu, Q; Goghari, VM; Honer, WG
  • Decreased caudate volume in neuroleptic-naïve psychotic patients
    Keshavan, MS; Rosenberg, D; Sweeney, JA; Pettegrew, JW
  • An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone
    Lang, DJ; Kopala, LC; Vandorpe, RA; Rui, Q; Smith, GN; Goghari, VM; Honer, WG
  • Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics
    Corson, PW; Nopoulos, P; Miller, DD; Arndt, S; Andreasen, NC
  • Schizophrenia, psychosis, and the basal ganglia
    Busatto, GF; Kerwin, RW
  • The basal ganglia and cognitive pattern generators
    Graybiel, AM
  • What are the functional consequences of neurocognitive deficits in schizophrenia?
    Green, MF
  • Functional magnetic resonance imaging evidence for disrupted basal ganglia function in schizophrenia
    Menon, V; Anagnoson, RT; Glover, GH; Pfefferbaum, A
  • "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry?
    Andreasen, NC; Paradiso, S; O'Leary, DS
  • Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study
    Crespo-Facorro, B; Paradiso, S; Andreasen, NC; O'Leary, DS; Watkins, GL; Boles Ponto, LL; Hichwa, RD
  • Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus
    Liddle, PF; Lane, CJ; Ngan, ET
  • Canadian clinical practice guidelines for the treatment of schizophrenia
  • Practice guideline for the treatment of patients with schizophrenia
  • The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
    Miller, AL; Chiles, JA; Chiles, JK; Crismon, ML; Rush, J; Shon, SP
  • Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade
    Fitzgerald, PB; Kapur, S; Caligiuri, MP; Jones, C; Silvestri, S; Remington, G; Zipursky, RB